Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (Nasdaq: ECOR) is a commercial-stage bioelectronic medicine and wellness company that regularly issues news on its non-invasive neuromodulation technologies, prescription therapies, and wellness and performance devices. This news feed aggregates company press releases, clinical study announcements, reimbursement developments, corporate updates, and other disclosures directly related to electroCore.
Readers can follow updates on electroCore’s prescription products, including gammaCore non-invasive vagus nerve stimulation (nVNS) and the Quell neurostimulator for chronic pain syndromes, as well as its handheld Truvaga and TAC-STIM devices for general wellness and human performance. News items have covered peer-reviewed studies on gammaCore in persistent post-concussion symptoms, controlled trials of TAC-STIM in active-duty Air Force trainees, and recognition of Truvaga Plus in consumer-focused awards.
The ECOR news stream also includes financial and corporate information such as quarterly results, revenue trends, private placements, participation in investor conferences, and changes to the board of directors and executive team. Regulatory and market access milestones, like reimbursement decisions for gammaCore Sapphire in Belgium, appear alongside product and clinical updates.
Investors, clinicians, and individuals interested in bioelectronic medicine can use this page to review electroCore’s historical and recent announcements in one place. For deeper analysis of any item, users can combine these news releases with the company’s SEC filings and other official documents accessible through related sections of the platform.
electroCore has provided an operating update, revealing a cash balance of $18.9 million at the end of Q2 2020. Despite the COVID-19 pandemic impacting their business, they reported revenue between $730,000 and $750,000, slightly exceeding Q1 performance. The company received an Emergency Use Authorization (EUA) for gammaCore™ to treat asthma in COVID-19 patients, with ongoing clinical trials in Spain and Pittsburgh. Additionally, orders from the VA/DoD grew, although shipped therapy months dropped due to pandemic disruptions.
electroCore, Inc. (Nasdaq: ECOR) reported an operating update for Q2 2020, citing a sequential revenue increase above $700,000, with total revenue expected between $730,000 and $750,000. The COVID-19 pandemic affected operations, leading to a decline in paid therapy months shipped to both the VA/DoD and OUS channels. However, the firm received an Emergency Use Authorization for gammaCore™ CV for asthma exacerbations related to COVID-19. Two clinical trials for gammaCore™ in COVID-19 patients are underway. Despite pandemic challenges, the company anticipates a recovery in key revenue channels.
electroCore, Inc. (Nasdaq: ECOR) will have its CEO, Dan Goldberger, participate in three investor conferences this month. The first is the Maxim Group/M-Vest COVID-19 Virtual Conference on July 16, where he'll join a panel discussing medical devices. The second conference is the Zooming with LD Micro presentation on July 21, followed by one-on-one virtual meetings. Lastly, the Canaccord Genuity 40th Annual Growth Conference is scheduled for August 11. The company focuses on non-invasive vagus nerve stimulation for treating migraines and cluster headaches.
electroCore, Inc. (Nasdaq: ECOR) plans to report its financial results for Q1 2020 on May 14, 2020, after market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results. The company specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies aimed at treating conditions like migraines and cluster headaches. With a commitment to improving patient outcomes, electroCore continues to innovate in the neurology and rheumatology sectors.